Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain.

Calvo Aller, E; Maroto, P; Kreif, N; González Larriba, JL; López-Brea, M; Castellano, D; Martí, B; Díaz Cerezo, S; (2011) Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain. Clinical & translational oncology, 13 (12). pp. 869-77. ISSN 1699-048X DOI: https://doi.org/10.1007/s12094-011-0748-0

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1007/s12094-011-0748-0

Abstract

Share

Download

Full text not available from this repository.

Downloads

View details

Metrics & Citations


Google Scholar